Význam u konkrétních onemocnění

Epidermoidní karcinomy plic

• Senzitivita CYFRA 21–1 kolem 55 %

Epidermoidní nádorů cervixu

• Spolu s SCC

Adenokarcinomy plic

• Senzitivita 28 %

Advanced non-small cell lung cancer

• Prognostic value of Cyfra 21-1 + CEA + NSE
• Serum samples from untreated NSCLC patients
• CEA, NSE and Cyfra 21-1 higher than 10, 13 and 3.5 ng/ml - considered as elevated.
• 264 patients (men, 87%)
• Cyfra 21-1, age, PS, stage as well as the combination of the three markers together
• Correlated with prognosis in univariate analysis
• Multivariate analysis
• Age nad or = 65 years (HR = 1.3 [1.02-1.70], p = 0.03)
• PS 2 (HR = 4.3 [3.13-6.11], p pod 0.0001)
• Cyfra 21-1 nad or = 3.5 ng/ml (HR = 1.3 [1.06-1.78], p = 0.01) [2]
• Combination of the three markers (HR = 1.06 [1.009-1.13], p = 0.02) remained prognostic determinants [2]

Karcinomy močového měchýře

• Senzitivita asi 30 % [1]

Karcinomy plic

Nádory hlavy a krku

• V séru je charakteristický

Non-small cell lung cancer

• 211 patients with non-small cell lung cancer
• Tumor marker sensitivity
• CYFRA 21-1: 76%
• CA 125: 55%
• CEA: 52%
• SCC: 33%
• NSE: 22% [1]
• One of the tumor markers was abnormally high
• In 87% of the patients with locoregional disease
• In 100% of the patients with metastases [1]
• Except for NSE, all tumor markers showed relationship with
• Tumor stage
• Histology [1]
• Abnormal CEA serum levels
• Mainly found in adenocarcinomas [1]
• CA 125
• Large-cell lung cancers (LCLC)
• Adenocarcinomas [1]
• CA 125 levels pod 60 U/ml nebo CEA pod 10 ng/ml
• Excluded with a probability of 82 and 91%
• Adenocarcinoma
• LCLC [1]
• SCC
• Squamous tumors
• 85% patients with SCC levels nad 2 ng/ml had squamous tumors [1]

Velkobuněčné karcinomy plic

• Senzitivita 35 %